Business
Resverlogix Notice of Conference Call & Webcast to Discuss ASSERT Clinical Trial Data
Resverlogix Notice of Conference Call & Webcast to Discuss ASSERT Clinical Trial Data
About this update from Resverlogix Corp.
[{"type":"text","content":"\n\n\n\n Nov. 15, 2010 (Canada NewsWire Group) -- \n\n#ReleaseContent TABLE\n{\n BORDER-COLLAPSE: collapse\n}\nTR.cnwUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 1px solid\n}\nTR.cnwDoubleUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 3px double\n}\nTR.cnwBoldUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 3px solid\n}\nTD.cnwUnderlinedCell\n{\n BORDER-BOTTOM: #000000 1px solid\n}\nTD.cnwDoubleUnderlinedCell\n{\n BORDER-BOTTOM: #000000 3px double\n}\nTD.cnwBoldUnderlinedCell\n{\n BORDER-BOTTOM: #000000 3px solid\n}\n#ReleaseContent TABLE.cnwBorderedTable TD\n{\n BORDER-RIGHT: black 1px solid;\n PADDING-RIGHT: 2px;\n BORDER-TOP: black 1px solid;\n PADDING-LEFT: 2px;\n PADDING-BOTTOM: 2px;\n BORDER-LEFT: black 1px solid;\n PADDING-TOP: 2px;\n BORDER-BOTTOM: black 1px solid;\n BORDER-COLLAPSE: collapse\n}\n#ReleaseContent TABLE TD\n{\n PADDING-RIGHT: 2px;\n PADDING-LEFT: 2px;\n PADDING-BOTTOM: 2px;\n PADDING-TOP: 2px\n}\n\n\nTSX Exchange Symbol: RVX\n\n\nCHICAGO and CALGARY, Nov. 15 /CNW/ - Resverlogix Corp. (TSX:RVX)\n announced today that it will host a live teleconference and webcast on\n Wednesday, November 17, 2010 at 1:30 pm Central/12:30 pm Mountain time.\n The purpose of the teleconference is to discuss the top line results of\n the Company's Phase 2 clinical trial (ASSERT) for RVX-208, an oral\n small molecule in development to treat atherosclerosis and\n cardiovascular disease.\n\n\nThe dial-in numbers for this event are toll free 1-800-319-4610 and\n international 1-604-638-5340. A link for this webcast will be posted\n onto the homepage of Resverlogix's website and can be accessed from the\n following address http://services.choruscall.com/links/resverlogix101117.html\n\n\nThe webcast will be available on the Resverlogix website for replay for\n a period of 45 days after the event.\n\n\nAbout Resverlogix Corp.\nResverlogix Corp. is a leading biotechnology company engaged in the\n development of novel therapies for important global medical markets\n with significant unmet medical needs. The NexVas™ PR program is the\n Company's primary focus which is to develop novel small molecules that\n enhance ApoA-1. These vital therapies address the burden of\n atherosclerosis and other important diseases such as Acute Coronary\n Syndrome, Diabetes, Alzheimer's disease, Peripheral Artery Disease and\n other vascular disorders....